📷 Image: Hindustan Times (via NewsData)
International
US Removes Tariffs on Indian Specialty Drugs and Ingredients
✍️ Hindustan Times
🗓 29 Sep 2026, 06:48 AM
👁 17
The United States has announced zero ad‑valorem tariffs on certain specialty drugs and their ingredients sourced from India and 19 other countries, easing export conditions for the pharma sector.
The United States has lifted ad‑valorem tariffs on a select group of specialty drugs and their ingredients that are manufactured in India and 19 other nations. The decision means that these goods will be imported into the U.S. without any tariff, reducing the cost for Indian pharmaceutical companies.
An ad‑valorem tariff is a percentage of the value of goods, as defined by the World Customs Organization. By setting the rate to zero, the U.S. government removes this additional cost layer for the specified products.
The move is expected to benefit Indian exporters, many of whom rely on specialty drugs for high‑margin sales. Lower import duties could make Indian products more competitive in the U.S. market.
The policy change is part of a broader U.S. strategy to streamline trade in critical medical supplies and to support global supply chains amid ongoing health challenges.
An ad‑valorem tariff is a percentage of the value of goods, as defined by the World Customs Organization. By setting the rate to zero, the U.S. government removes this additional cost layer for the specified products.
The move is expected to benefit Indian exporters, many of whom rely on specialty drugs for high‑margin sales. Lower import duties could make Indian products more competitive in the U.S. market.
The policy change is part of a broader U.S. strategy to streamline trade in critical medical supplies and to support global supply chains amid ongoing health challenges.